Myasthenia Gravis Updates

📧 EM Note Newsletter https://forms.gle/8boToiKDXVE3V8U19 Signup to get free weekly PDF via email. PS: Please join our membership for more perks (members can request for specific PDF file by posting in the EM Note YouTube Membership section). Homepage: EMNote.org ■ 🚩Membership: https://tinyurl.com/joinemnote 🚩ACLS Lecture: https://tinyurl.com/emnoteacls This lecture offers an extensive update on the rapid advancements in Myasthenia Gravis (MG) treatment since 2016, noting that the disease is transitioning from being managed to potentially curable. The text details five major breakthroughs, starting with the MGTX trial providing gold-standard proof that thymectomy is highly effective, enabling patients to significantly reduce or stop steroid use. Further innovations include the development of complement inhibitors like ravulizumab and zilucoplan, which directly shield the neuromuscular junction from immune system damage. Another critical development is the introduction of FcRn inhibitors such as efgartigimod, which rapidly clear pathogenic antibodies, providing a non-mechanical alternative similar to plasma exchange. The source also highlights that rituximab has become a standard-of-care treatment, especially for MuSK-MG patients, and emphasizes the new focus on treating "disease age" in late-onset MG cases.